Answers are grounded in this paper and cite their sources.
Real-world evidence demonstrates that neoadjuvant TRK inhibitors improve responses in advanced sarcomas, suggesting preferred treatment over chemotherapy.
In children with NTRK fusion-positive sarcomas, upfront TRK inhibition yielded faster, deeper responses and eliminated mutilating surgery in our cohort. These data support TRK inhibitors as preferred neoadjuvant options, particularly to facilitate non-morbid resections and to avoid functional disability.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: